US 12,138,034 B2
Gastroretentive articles for alcohol sensing
Robert S. Langer, Newton, MA (US); Carlo Giovanni Traverso, Newton, MA (US); Malvika Verma, Cambridge, MA (US); Feyisope Eweje, Jacksonville, NC (US); Christoph Winfried Johannes Steiger, Cambridge, MA (US); Junwei Li, Cambridge, MA (US); Nhi Phan, Somerville, MA (US); Hen-Wei Huang, Cambridge, MA (US); Jacqueline Chu, Boston, MA (US); and John Ashraf Fou Salama, Cambridge, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US); The Brigham and Women's Hospital, Inc., Boston, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); The Brigham and Women's Hospital, Inc., Boston, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed on Dec. 15, 2023, as Appl. No. 18/541,818.
Application 18/541,818 is a continuation of application No. 17/318,040, filed on May 12, 2021, granted, now 11,850,034.
Claims priority of provisional application 63/023,280, filed on May 12, 2020.
Prior Publication US 2024/0108241 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/07 (2006.01); A61B 5/00 (2006.01)
CPC A61B 5/073 (2013.01) [A61B 5/4845 (2013.01); A61B 2562/02 (2013.01); A61B 2562/162 (2013.01); A61B 2562/164 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A gastric residence article, comprising:
a sensor associated with the gastric residence article; and
one or more drug delivery modules in electrical and/or wireless communication with the sensor;
wherein the gastric residence article is configured to be administered to a subject and to be retained at a location internal to the subject for at least 24 hours,
wherein the gastric residence article has a first configuration sized and adapted for transesophageal administration to a subject,
wherein the gastric residence article has a second configuration sized and adapted such that the gastric residence article is retained in the stomach and prevented from passing through the pylorus, and
wherein the sensor, upon detection of one or more biophysical conditions in the location internal the subject, is configured to trigger release of at least one therapeutic agent from the one or more drug delivery modules to the location internal the subject.